Advertisement

Parkinson Disease

  • Jacqui E. AllenEmail author
  • Anna Miles
Chapter
  • 60 Downloads

Abstract

Parkinson disease is the most common neurodegenerative disease reported worldwide and presents multiple diverse and disparate manifestations over a prolonged disease course. At any point, speech and swallowing functions may be disturbed, and dysfunctional swallowing, leading to aspiration pneumonia, is the most common cause of death. Current treatments demonstrate limited benefit for speech and swallowing impairments, but novel approaches and greater insight into disease pathogenesis offer hope of improved management of Parkinson disease and its sequelae.

Keywords

Parkinson disease Dysphagia Aspiration pneumonia α-Synucleinopathy Hypophonia Lee Silverman Voice Technique Choir therapy 

Abbreviations

AADC

Aromatic amino acid decarboxylase

AD

Autosomal dominant

AR

Autosomal recessive

BBB

Blood-brain barrier

COMT

Catechol-O-methyltransferase

DA

Dopamine

DJ-1

DJ-1 parkinsonism associated deglycase∗

LRRK2

Leucine-rich repeat kinase 2∗

Parkin

Parkin (PARK2)∗

PD

Parkinson disease

PINK1

PTEN-induced putative kinase 1∗

RLN

Recurrent laryngeal nerve

SNCA

α-Synuclein gene (also called PARK1/4)∗

UES

Upper esophageal sphincter

VF

Vocal folds

VFSS

Video-fluoroscopic swallowing study

Gene names for genes associated with familial Parkinson disease

References

  1. 1.
    Videira PAQ, Castro-Caldas M. Linking glycation and glycosylation with inflammation and mitochondrial dysfunction in Parkinson’s disease. Front Neurosci. 2018;12:381.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Kulisevsky J, Oliveira L, Fox SH. Update in therapeutic strategies for Parkinson’s disease. Curr Opin Neurol. 2018;31(4):439–47.PubMedCrossRefPubMedCentralGoogle Scholar
  3. 3.
    Ko EJ, Chae M, Cho SR. Relationship between swallowing function and maximum phonation time in patients with Parkinsonism. Ann Rehabil Med. 2018;42(3):425–32.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Plowman-Prine EK, Sapienza CM, Okun MS, Pollock SL, Jacobson C, Wu SS, et al. The relationship between quality of life and swallowing in Parkinson’s disease. Mov Disord. 2009;24(9):1352–8.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    van Hooren MR, Baijens LW, Voskuilen S, Oosterloo M, Kremer B. Treatment effects for dysphagia in Parkinson’s disease: a systematic review. Parkinsonism Relat Disord. 2014;20(8):800–7.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    van Hooren MR, Baijens LW, Vos R, Pilz W, Kuijpers LM, Kremer B, et al. Voice- and swallow-related quality of life in idiopathic Parkinson’s disease. Laryngoscope. 2016;126(2):408–14.PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Tomita S, Oeda T, Umemura A, Kohsaka M, Park K, Yamamoto K, et al. Video-fluoroscopic swallowing study scale for predicting aspiration pneumonia in Parkinson’s disease. PLoS One. 2015;10(8):e0136722.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Hobson P, Meara J. Mortality and quality of death certification in a cohort of patients with Parkinson’s disease and matched controls in North Wales, UK at 18 years: a community-based cohort study. BMJ Open. 2018;8(2):e018969.PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Mantri S, Fullard ME, Beck J, Willis AW. State-level prevalence, health service use, and spending vary widely among Medicare beneficiaries with Parkinson disease. NPJ Parkinsons Dis. 2019;5(1)  https://doi.org/10.1038/s41531-019-0074-8.
  10. 10.
    Dorsey ER, Sherer T, Okum MS, Bloem BR. The emerging evidence of the Parkinson pandemic. J Park Dis. 2018;8(s1):S3–8.Google Scholar
  11. 11.
    Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003;24(2):197–211.PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    Braak H, Del Tredici K. Neuropathological staging of brain pathology in sporadic Parkinson’s disease: separating the wheat from the chaff. J Park Dis. 2017;7(s1):S71–85.Google Scholar
  13. 13.
    Mori F, Tanji K, Zhang H, Kakita A, Takahashi H. Wakabayashi K. alpha-synuclein pathology in the neostriatum in Parkinson’s disease. Acta Neuropathol. 2008;115(4):453–9.PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Zhang QS, Heng Y, Yan YH, Chen NH. Pathological α-synuclein exacerbates the progression of Parkinson’s disease through microglial activation. Toxicol Lett. 2017;265:30–7.PubMedCrossRefPubMedCentralGoogle Scholar
  15. 15.
    Vijitruth R, Liu M, Choi DY, Nguyen XV, Hunter RL, Bing G. Cyclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model of Parkinson’s disease. J Neuroinflammation. 2006;3:6.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Leopold N, Kagel M. Pharyngoesophageal dysphagia in Parkinson’s disease. Dysphagia. 1997;12(1):11–8; discussion 19–20PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Warnecke T, Suttrupa I, Schroder JB, Osadab N, Oelenberg S, Hamachera C, et al. Levodopa responsiveness of dysphagia in advanced Parkinson’s disease and reliability testing of the FEES levodopa test. Parkinsonism Relat Disord. 2016;28:100–6.PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Warnecke T, Oelenberg S, Teismann I, Hamacher C, Lohmann H, Ringelstein EB, Dziewas R. Endoscopic characteristics and levodopa responsiveness of swallowing function in progressive supranuclear palsy. Mov Disord. 2010;25(9):1239–45.PubMedCrossRefPubMedCentralGoogle Scholar
  19. 19.
    Reichmann H. Clinical criteria for the diagnosis of Parkinson’s disease. Neurodegener Dis. 2010;7(5):284–90.PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Brooks DJ. Parkinson’s disease: diagnosis. Parkinsonism Relat Disord. 2012;18(Suppl 1):S31–3.PubMedCrossRefGoogle Scholar
  21. 21.
    Hughes KC, Gao X, Baker JM, Stephen C, Kim IY, Valeri L, Schwarzschild MA, Ascherio A. Non-motor features of Parkinson’s disease in a nested case-control study of US men. J Neurol Neurosurg Psychiatry. 2018;89(12):1288–95.PubMedCrossRefGoogle Scholar
  22. 22.
    Novakovic D, MacKay S. Adult obstructive sleep apnoea and the larynx. Curr Opin Otolaryngol Head Neck Surg. 2015;23(6):464–9.PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Dedhia RC, Rosen CA, Soose RJ. What is the role of the larynx in adult obstructive sleep apnea? Laryngoscope. 2014;124(4):1029–34.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Crosta F, Desideri G, Marini C. Obstructive sleep apnea syndrome in Parkinson’s disase and other parkinsonisms. Funct Neurol. 2017;32(3):137–41.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Bagheri H, Damase-Michel C, Lapeyre-Mestre M, Cismondo S, O’Connell D, Senat JM, et al. A study of salivary secretion in Parkinson’s disease. Clin Neuropharmacol. 1999;22(4):213–5.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Sato H, Yamamoto T, Sato FY, Murata M. Dysphagia causes symptom fluctuations after oral L-dopa treatment in a patient with Parkinson disease. Case Rep Neurol. 2018;10(1):101–7.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Mu L, Sobotka S, Chen J, Su H, Sanders I, Adler CH, et al. α-synuclein pathology and axonal degeneration of the peripheral motor nerves innervating pharyngeal muscles in Parkinson’s disease. J Neuropathol Exp Neurol. 2013;72(2):119–29.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Miles A, Jardine M, Johnston F, de Lisle M, Friary P, Allen J. Effect of Lee Silverman Voice Treatment (LSVT®) on swallowing and cough function in people with Parkinson’s disease. J Neurol Sci. 2017;383:180–7.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Suttrup I, Warnecke T. Dysphagia in Parkinson’s disease. Dysphagia. 2016;31(1):24–32.PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Suttrup I, Suttrup J, Suntrup-Krueger S, Siemer ML, Bauer J, Hamacher C, et al. Esophageal dysfunction in different stages of Parkinson’s disease. Neurogastroenterol Motil 2017.  https://doi.org/10.1111/nmo.12915. Epub ahead of print.CrossRefGoogle Scholar
  31. 31.
    Derrey S, Chastan N, Maltete D, Verin E, Dechelotte P, Lefaucheur R, et al. Impact of deep brain stimulation on pharyngo-esophageal motility: a randomized cross-over study. Neurogastroenterol Motil. 2015;27(9):1214–22.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Sung HY, Kim JS, Lee KS, Kim YI, Song IU, Chung SW, et al. The prevalence and patterns of pharyngoesophageal dysmotility in patients with early stage Parkinson’s disease. Mov Disord. 2010;25(14):2361–8.PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    El-Sharkawi A, Ramig L, Logemann JA, Pauloski BR, Rademaker AW, Smith CH, et al. Swallowing and voice effects of Lee Silverman Voice Treatment (LSVT): a pilot study. J Neurol Neurosurg Psychiatry. 2002;72(1):31–6.PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Bachmann CG, Zapf A, Brunner E, Trenkwalder C. Dopaminergic treatment is associated with decreased body weight in patients with Parkinson’s disease and dyskinesias. Eur J Neurol. 2009;16(8):895–901.PubMedCrossRefGoogle Scholar
  35. 35.
    Sheard JM, Ash S, Silburn PA, Kerr GK. Prevalence of malnutrition in Parkinson’s disease: a systematic review. Nutr Rev. 2011;69(9):520–32.PubMedCrossRefGoogle Scholar
  36. 36.
    Plowman-Prine EK, Okun MS, Sapienza CM, Shrivastav R, Fernandez HH, Foote KD, et al. Perceptual characteristics of Parkinsonian speech: a comparison of the pharmacological effects of levodopa across speech and non-speech motor systems. Neuropsychol Rehabil. 2009;24(2):131–44.Google Scholar
  37. 37.
    Moon S, Schmidt M, Smirnova IV, Colgrove Y, Liu W. Qigong exercise may reduce serum TNF-α levels and improve sleep in people with Parkinson’s disease: a pilot study. Medicines (Basel). 2017;4(2)  https://doi.org/10.3390/medicines4020023.PubMedCentralCrossRefGoogle Scholar
  38. 38.
    Park A, Zid D, Russell J, Malone A, Rendon A, Wehr A, Li X. Effects of a formal exercise program on Parkinson’s disease: a pilot study using a delayed start design. Parkinsonism Relat Disord. 2014;20(1):106–11.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Fox CM, Ramig LO, Ciucci MR, Sapir S, McFarland DH, Farley BG. The science and practice of LSVT/LOUD: neural plasticity-principled approach to treating individuals with Parkinson’s disease and other neurological disorders. Semin Speech Lang. 2006;27(4):283–99.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Sapir S, Ramig L, Fox C. The Lee Silverman Voice Treatment for voice, speech and other orofacial disorders in patients with Parkinson’s disease. Future Neurol. 2006;1:563–70.CrossRefGoogle Scholar
  41. 41.
    Sapir S, Spielman JL, Ramig LO, Story BH, Fox C. Effects of intensive voice treatment the Lee Silverman Voice Treatment (LSVT) on vowel articulation in dysarthric individuals with idiopathic Parkinson’s disease: acoustic and perceptual findings. J Speech Lang Hear Res. 2007;50(4):899–912.PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Pitts T, Bolser D, Rosenbek J, Troche M, Okun M, Sapienza C. Impact of expiratory muscle strength training on voluntary cough and swallow function in Parkinson disease. Chest. 2009;135(5):1301–8.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Johnson DN, Herring HJ, Daniels SK. Dysphagia management in stroke rehabilitation. Curr Phys Med Rehabil Rep. 2014;2(4):207–18.CrossRefGoogle Scholar
  44. 44.
    Athukorala RP, Jones RD, Sella O, Huckabee ML. Skill training for swallowing rehabilitation in patients with Parkinson’s disease. Arch Phys Med Rehabil. 2014;95(7):1374–82.PubMedCrossRefPubMedCentralGoogle Scholar
  45. 45.
    Troche MS, Okun MS, Rosenbek JC, Musson N, Fernandez HH, Rodriguez R, et al. Aspiration and swallowing in Parkinson disease and rehabilitation with EMST: a randomized trial. Neurology. 2010;75(21):1912–9.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Park JS, Oh DH, Hwang NK, Lee JH. Effects of neuromuscular electrical stimulation in patients with Parkinson’s disease and dysphagia: a randomized, single-blind placebo-controlled trial. NeuroRehabilitation. 2018;42(4):457–63.PubMedCrossRefPubMedCentralGoogle Scholar
  47. 47.
    Troche MS, Rosenbek JC, Okun MS, Sapienza CM. Detraining outcomes with expiratory muscle strength training in Parkinson’s disease. J Rehabil Res Dev. 2014;51(2):305–10.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Ludlow CL. Electrical neuromuscular stimulation in dysphagia: current status. Curr Opin Otolaryngol Head Neck Surg. 2010;18(3):159–64.PubMedCrossRefPubMedCentralGoogle Scholar
  49. 49.
    Russell JA, Ciucci MR, Connor NP, Schallert T. Targeted exercise therapy for voice and swallow in persons with Parkinson’s disease. Brain Res. 2010;1341:3–11.PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Sapir S, Ramig LO, Fox CM. Intensive voice treatment in Parkinson’s disease: Lee Silverman voice treatment. Expert Rev Neurother. 2011;11(6):815–30.PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    Ramig LO, Sapir S, Fox C. Changes in vocal loudness following intensive voice treatment (LSVT) in individuals with Parkinson’s disease: a comparison with untreated peoples and normal age-matched controls. Mov Disord. 2001;16(1):79–83.PubMedCrossRefPubMedCentralGoogle Scholar
  52. 52.
    Ramig LO, Sapir S, Countryman S, Pawlas AA, O’Brien C, Hoehn M, Thompson LL. Intensive voice treatment (LSVT) for peoples with Parkinson's disease: a 2-year follow up. J Neurosurg Psychol. 2001;71(4):493–8.CrossRefGoogle Scholar
  53. 53.
    Ramig LO, Fox C, Sapir S. Parkinson’s disease: speech and voice disorders and their treatment with the Lee Silverman Voice Treatment. Semin Speech Lang. 2004;25(2):169–80.CrossRefGoogle Scholar
  54. 54.
    Constantinescu G, Theodoros D, Russell T, Ward E, Wilson S, Wootton R. Treating disordered speech and voice in Parkinson’s disease online: a randomized controlled non-inferiority trial. Int J Lang Commun Disord. 2011;46(1):1–16.PubMedPubMedCentralGoogle Scholar
  55. 55.
    Manor Y, Posen J, Amir O, Dori N, Giladi N. A group intervention model for speech and communication skills in patients with Parkinson’s disease initial observations. Comm Dis Quart. 2005;26(2):94–101.CrossRefGoogle Scholar
  56. 56.
    Plourde JMH, Purdy SC, Moore C, Friary P, Brown R, McCann C. Gavel Club for people with aphasia: communication confidence and quality of communication life. Aphasiology. 2019;33(1):73–93.CrossRefGoogle Scholar
  57. 57.
    Fogg-Rogers L, Buetow S, Talmage A, McCann C, Leão SHS, Tippett L, et al. Choral singing therapy following stroke or Parkinson’s disease: an exploration of participants’ experiences. Disabil Rehabil. 2016;38(10):952–62.PubMedCrossRefPubMedCentralGoogle Scholar
  58. 58.
    Seagall LE. The effect of group singing on the voice and swallow function of healthy, sedentary, older adults: a pilot study. Arts Psychother. 2017;55:40–5.CrossRefGoogle Scholar
  59. 59.
    Stegemoller EL, Radig H, Hibbing P, Wingate J, Sapienza C. Effects of singing on voice, respiratory control and quality of life in persons with Parkinson’s disease. Disabil Rehabil. 2017;39(6):594–600.PubMedCrossRefPubMedCentralGoogle Scholar
  60. 60.
    Di Benedetto P, Cavazzon M, Mondolo F, Rugiu G, Peratoner A, Biasutti E. Voice and choral singing treatment: a new approach for speech and voice disorders in Parkinson’s disease. Eur J Phys Rehabil Med. 2009;45(1):13–9.PubMedGoogle Scholar
  61. 61.
    Han EY, Yn JY, Chong HJ, Choi KG. Individual therapeutic singing program for vocal quality and depression in Parkinson’s disease. J Mov Disord. 2018;11(3):121–8.PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    Stegemoller EL, Hibbing P, Radig H, Wingate J. Therapeutic singing as an early intervention for swallowing in persons with Parkinson’s disease. Complement Ther Med. 2017;31:127–33.PubMedCrossRefGoogle Scholar
  63. 63.
    Elefant C, Baker FA, Lota M, Lagesen SK, Skeie GO. The effect of group music therapy on mood, speech, and singing in individuals with Parkinson’s disease – a feasibility study. J Music Ther. 2012;49(3):278–302.PubMedCrossRefGoogle Scholar
  64. 64.
    Mathew D, Sundar S, Subramaniam E, Parmar PN. Music therapy as a group singing improves Geriatric Depression Scale score and loneliness in institutionalised geriatric adults with mild depression: a randomised controlled study. Int J Educ Psychol Res. 2017;3(1):6–10.Google Scholar
  65. 65.
    Talmage A, Ludlam S, Leão S, Fogg-Rogers LA, Purdy SC. Leading the celebration choir: the choral singing therapy protocol and the role of the music therapist in a social singing group for adults with neurological conditions. NZ. J Music Ther. 2013;11:7–50.Google Scholar
  66. 66.
    Annus A, Vécsei L. Spotlight on opicapone as an adjunct to levodopa in Parkinson’s disease: design, development and potential place in therapy. Drug Des Devel Ther. 2017;11:143–51.PubMedPubMedCentralCrossRefGoogle Scholar
  67. 67.
    Elkurd MT, Bahroo LB, Pahwa R. The role of extended-release amantadine for the treatment of dyskinesia in Parkinson’s disease patients. Neurodegener Dis Manag. 2018;8(2):73–80.PubMedCrossRefPubMedCentralGoogle Scholar
  68. 68.
    Radad K, Gille G, Rausch WD. Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson’s disease. Pharmacol Rep. 2005;57(6):701–12.PubMedPubMedCentralGoogle Scholar
  69. 69.
    Ogawa T, Oyama G, Hattori N. Transdermal rotigotine patch in Parkinson’s disease with a history of intestinal operation. BMJ Case Rep. 2018;  https://doi.org/10.1136/bcr-2017-223722.
  70. 70.
    Dafotakis M, Sparing R, Juzek A, Block F, Kosinski CM. Transdermal dopaminergic stimulation with rotigotine in Parkinsonian akinetic crisis. J Clin Neurosci. 2009;16(2):335–7.PubMedCrossRefPubMedCentralGoogle Scholar
  71. 71.
    Hattori N, Hasegawa K, Sato K, Mitsuyama E, Numachi Y. Clinical evaluation of ropinirole controlled-release formulation at 18-24mg/day in Japanese patients with Parkinson’s disease. Parkinsonism Relat Disord. 2017;40:33–9.PubMedCrossRefPubMedCentralGoogle Scholar
  72. 72.
    Olanow CW, Kieburtz K, Leinonen M, Elmer L, Giladi N, Hauser RA, et al. A randomized trial of low-dose Rasagiline and pramipexole combination (P2B001) in early Parkinson’s disease. Mov Disord. 2017;32(5):783–9.PubMedCrossRefPubMedCentralGoogle Scholar
  73. 73.
    Cansino-Torres MA, Sandoval-Rodríguez V, Sáenz-Farrett M, Zúñiga-Ramírez C. Allergy to carbidopa. Clin Neuropharmacol. 2018;41(2):75–9.PubMedCrossRefPubMedCentralGoogle Scholar
  74. 74.
    de Rus Jacquet A, Timmers M, Ma SY, Thieme A, McCabe GP, Vest JHC, et al. Lumbee traditional medicine: neuroprotective activities of medicinal plants used to treat Parkinson’s disease-related symptoms. J Ethnopharmacol. 2017;206:408–25.PubMedPubMedCentralCrossRefGoogle Scholar
  75. 75.
    Schneeberger A, Mandler M, Mattner F, Schmidt W. Vaccination for Parkinson’s disease. Parkinsonism Relat Disord. 2012;18(Suppl 1):S11–3.PubMedCrossRefPubMedCentralGoogle Scholar
  76. 76.
    Oad MA, Miles A, Lee A, Lambie A. Medicine administration in people with Parkinson’s disease in New Zealand: an interprofessional, stakeholder-driven online survey. Dysphagia. 2019;34(1):119–28.PubMedCrossRefPubMedCentralGoogle Scholar
  77. 77.
    Patel K. Optimising medication for Parkinson’s disease patients with dysphagia. Br J Community Nurs. 2015;20(7):322–6.PubMedCrossRefGoogle Scholar
  78. 78.
    Foppa AA, Chemello C, Vargas-Peláez CM, Farias MR. Medication therapy management service for patients with Parkinson’s disease: a before-and-after study. Neurol Ther. 2016;5(1):85–99.PubMedPubMedCentralCrossRefGoogle Scholar
  79. 79.
    Triadafilopoulos G, Gandhy R, Barlow C. Pilot cohort study of endoscopic botulinum neurotoxin injection in Parkinson’s disease. Parkinsonism Relat Disord. 2017;44:33–7.PubMedCrossRefGoogle Scholar
  80. 80.
    Tate P, Pandey S. Botulinum toxin in movement disorders. Neurol India. 2018;66(Suppl 1):79–89.Google Scholar
  81. 81.
    Born LJ, Hamed RH, Rikkers LF, Pfeiffer RF, Quigley EM. Cricopharyngeal dysfunction in Parkinson’s disease: role in dysphagia and response to myotomy. Mov Disord. 1996;11(1):53–8.PubMedCrossRefPubMedCentralGoogle Scholar
  82. 82.
    Olchik MR, Ghisi M, Ayres A, Schuh AFS, Oppitz PP, de Mello Rieder CR. The impact of deep brain stimulation on the quality of life and swallowing in individuals with Parkinson’s disease. Int Arch Otorhinolaryngol. 2018;22(2):125–9.PubMedCrossRefPubMedCentralGoogle Scholar
  83. 83.
    Xie T, Bloom L, Padmanaban M, Bertacchi B, Kang W, MacCracken E, et al. Long-term effect of low frequency stimulation of STN on dysphagia, freezing of gait and other motor symptoms in PD. J Neurol Neurosurg Psychiatry. 2018;89(9):989–94.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of OtolaryngologyNorth Shore Hospital AucklandAucklandNew Zealand
  2. 2.The University of AucklandAucklandNew Zealand
  3. 3.Department of Speech ScienceThe University of AucklandAucklandNew Zealand

Personalised recommendations